Cargando…
Combining Lovastatin and Minocycline for the Treatment of Fragile X Syndrome: Results From the LovaMiX Clinical Trial
Background: Limited success of previous clinical trials for Fragile X syndrome (FXS) has led researchers to consider combining different drugs to correct the pleiotropic consequences caused by the absence of the Fragile X mental retardation protein (FMRP). Here, we report the results of the LovaMiX...
Autores principales: | Champigny, Camille, Morin-Parent, Florence, Bellehumeur-Lefebvre, Laurence, Çaku, Artuela, Lepage, Jean-François, Corbin, François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763805/ https://www.ncbi.nlm.nih.gov/pubmed/35058813 http://dx.doi.org/10.3389/fpsyt.2021.762967 |
Ejemplares similares
-
Hyperexcitability and impaired intracortical inhibition in patients with fragile-X syndrome
por: Morin-Parent, Florence, et al.
Publicado: (2019) -
Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome
por: Laroui, Asma, et al.
Publicado: (2022) -
New insights of altered lipid profile in Fragile X Syndrome
por: Çaku, Artuela, et al.
Publicado: (2017) -
Association of lipid rafts cholesterol with clinical profile in fragile X syndrome
por: Toupin, Amanda, et al.
Publicado: (2022) -
Alteration of Fatty Acid Profile in Fragile X Syndrome
por: Abolghasemi, Armita, et al.
Publicado: (2022)